Anti-hypertensive Drugs Market To Reach $30.69 Billion By 2030

Anti-hypertensive Drugs Market Growth & Trends

The global anti-hypertensive drugs market size is expected to reach USD 30.69 billion by 2030, expandingat a CAGR of 3.91% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising patient base of high blood pressure is the primary factor propelling market growth. Moreover, increasing cases of chronic diseases such as obesity, cancer, and heart disease and innovations in drug discovery & personalized medicine are increasing the growth of anti-hypertensive drugs market.

Presence of strong product in the pipeline demonstrating positive results is a major factor driving the demand for anti-hypertensive drugs market. For instance, in September 2023, Alnylam Pharmaceuticals, Inc. announced the phase 2 study on an investigation drug for the treatment of hypertension, zilebesiran, met the primary end-point and demonstrated significant reduction in the systolic BP (24 hour mean). Zilebesiran is an RNAi therapeutic targeting angiotensinogen which is administered subcutaneously and is expected to target high unmet need in populations.

The growing prevalence of diabetes is fueling the anti-hypertensive drugs market growth, as hypertension is a common complication of diabetes. Over time, hypertension can damage the heart, blood vessels, kidneys, and other organs. As the prevalence of diabetes is growing, the demand for anti-hypertensive drugs is expected to increase. According to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults between the ages of 20-79 years are living with diabetes, and it is expected to reach 643 million by 2030.

Government funding for R&D activities and distribution is playing a role in boosting the market growth by making anti-hypertensive drugs more affordable, improving access, and increasing competition. For instance, in August 2023 , Eazymed Technologies Pvt Ltd. raised USD 500,000 from the Tamil Nadu Emerging Sector Seed Fund in India. The company will utilize the fund on new ventures in the supply chain, such as working directly with pharmaceutical companies to expand their presence in tier 2-3 cities. Such initiatives are boosting the anti-hypertensive drugs market growth.

Moreover, rising approvals of new anti-hypertensive drugs encourage pharmaceutical companies to invest in research & development of novel and effective treatment options, which is expected to offer lucrative opportunities for the key players. For instance, in May 2022, the FDA approved Tyvaso DPI (treprostinil) inhalation powder. Tyvaso DPI is a dry powder inhaler that delivers treprostinil, a vasodilator, directly to the lungs. Treprostinil works by dilating the pulmonary arteries, which reduces blood pressure in the lungs and improves exercise capacity.

 Request a free sample copy or view report summary: Anti-hypertensive Drugs Market Report

Anti-hypertensive Drugs Market Report Highlights

• Based on drug class, the calcium channel blockers segment dominated the market in 2023 owing to their intrinsic property in combination with other anti-hypertensive drugs

• Based on type, the primary hypertension segment held the largest segment share of the market in 2023, owing to the increasing geriatric population and changing lifestyle factors, such as diet, physical inactivity, obesity, smoking, and excessive alcohol consumption

• Based on route of administration, the oral segment held the largest share due to its convenience, effectiveness, and patient-centered approach

• Based on distribution channel, the hospital pharmacies dominated the market, owing to the rise in hospitals worldwide, offering a wide range of healthcare services

• North America has established a strong regional position with a 37.55% market share owing to the increasing investment by private players, favorable government and insurance policies, technological advancements, and key regional operating players

Anti-hypertensive Drugs Market Segmentation

Grand View Research has segmented the global anti-hypertensive drugs market based on drug class, type, route of administration, distribution channel, and region.

Anti-hypertensive Drugs, Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Diuretics

• ACE Inhibitors

• Calcium Channel Blockers

• Beta-adrenergic Blockers

• Vasodilators

• Others

Anti-hypertensive Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Primary Hypertension

• Secondary Hypertension

Anti-hypertensive Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectables

• Others

Anti-hypertensive Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Pharmacy

• Hospital Pharmacy

• Online Pharmacy

Anti-hypertensive Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• South Korea

• Australia

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait
  

List of Key Players in Anti-hypertensive Drugs Market

• Sanofi

• Boehringer Ingelheim International GmbH

• Novartis AG

• Johnson & Johnson Services, Inc.

• DAIICHI SANKYO COMPANY, LIMITED.

• Merck & Co., Inc.

• AstraZeneca

• Pfizer Inc.

• Lupin

• Sun Pharmaceutical Industries Ltd.